|
1. Ma, Y., C. Kowolik, P.M. Swiderski, M. Kortylewski, H. Yu, D.A. Horne, R. Jove, O.L. Caballero, A.J. Simpson, F.T. Lee, V. Pillay, and A.M. Scott, Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol, 2011.
2. Garrett, T.P., Burgess, A.W., Gan, H.K., Luwor, R.B., Cartwright, G., Walker, F., Orchard, S.G., Clayton, A.H., Nice, E.C., Rothacker, J., Catimel, B., Cavenee, W.K., Old, L.J., Stockert, E., Ritter, G., Adams, T.E., Hoyne, P.A., Wittrup, D., Chao, G., Cochran, J.R., Luo, C., Lou, M., Huyton, T., Xu, Y., Fairlie, W.D., Yao, S., Scott, A.M., and Johns, T.G., Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A, 2009. 106(13): p. 5082-7.
3. Herbertson, R.A., Tebbutt, N.C., Lee, F.T., Macfarlane, D.J., Chappell, B., Micallef, N., Lee, S.T., Saunder, T., Hopkins, W., Smyth, F.E., Wyld, D.K., Bellen, J., Sonnichsen, D.S., Brechbiel, M.W., Murone, C., and Scott, A.M., Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers. Clin Cancer Res, 2009. 15(21): p. 6709-15.
4. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate, 2009. 69(1): p. 92-104.
5. Scott, A.M., Gunawardana, D.H., Kelley, B., Stuckey, J.G., Byrne, A.J., Ramshaw, J.E., and Fulham, M.J., PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med, 2008. 49(9): p. 1451-7.
6. Scott, A.M., Lee, F.T., Tebbutt, N., Herbertson, R., Gill, S.S., Liu, Z., Skrinos, E., Murone, C., Saunder, T.H., Chappell, B., Papenfuss, A.T., Poon, A.M., Hopkins, W., Smyth, F.E., MacGregor, D., Cher, L.M., Jungbluth, A.A., Brechbiel, M.W., Murphy, R., Burgess, A.W., Hoffman, E.W., Johns, T.G., and Old, L.J., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A, 2007. 104(10): p. 4071-6.
 Click Here For More
|
